Literature DB >> 27939746

Non-Invasive Assessment of Pulmonary Vascular Resistance in Pulmonary Hypertension: Current Knowledge and Future Direction.

Pyi Naing1, Harveen Kuppusamy2, Gregory Scalia3, Graham S Hillis4, David Playford2.   

Abstract

Pulmonary Hypertension (PHT) is relatively common, dangerous and under-recognised. Pulmonary hypertension is not a diagnosis in itself; it is caused by a number of differing diseases each with different treatments and prognoses. Therefore, timely and accurate recognition of the underlying cause for PHT is essential for appropriate management. This is especially true for patients with Pulmonary Arterial Hypertension (PAH) in the current era of disease-specific drug therapy. Measurement of Pulmonary Vascular Resistance (PVR) helps separate pre-capillary from post-capillary PHT, and is measured with right heart catheterisation (RHC). Echocardiography has been used to derive a number of non-invasive surrogates for PVR, with varying accuracy. Ultimately, the goal of non-invasive assessment of PVR is to separate PHT due to left heart disease from PHT due to increased PVR, to help streamline investigation and subsequent treatment. In this review, we summarise the physiology and pathophysiology of pulmonary blood flow, the various causes of pulmonary hypertension, and non-invasive surrogates for PVR.
Copyright © 2016 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). All rights reserved.

Entities:  

Keywords:  Doppler echocardiography; Heart failure with preserved ejection fraction (HFpEF); Pulmonary arterial hypertension; Pulmonary hypertension (PHT); Pulmonary vascular resistance (PVR)

Mesh:

Year:  2016        PMID: 27939746     DOI: 10.1016/j.hlc.2016.10.008

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  6 in total

Review 1.  Pulmonary hypertension in low- and middle-income countries with focus on sub-Saharan Africa.

Authors:  Anastase Dzudie; Bonaventure Suiru Dzekem; Dike B Ojji; Andre Pascal Kengne; Ana Olga Mocumbi; Karen Sliwa; Friedrich Thienemann
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

2.  Echocardiographic evolution of pulmonary hypertension in female patients with hyperthyroidism.

Authors:  Cristina Tudoran; Mariana Tudoran; Mihaela Vlad; Melania Balas; Gheorghe Nicusor Pop; Florina Parv
Journal:  Anatol J Cardiol       Date:  2018-09       Impact factor: 1.596

3.  Serum uric acid is associated with disease severity and may predict clinical outcome in patients of pulmonary arterial hypertension secondary to connective tissue disease in Chinese: a single-center retrospective study.

Authors:  Jingya Wang; Yuanyuan Wang; Xiaodi Li; Yingheng Huang; Xiaoxuan Sun; Qiang Wang; Miaojia Zhang
Journal:  BMC Pulm Med       Date:  2020-10-19       Impact factor: 3.317

4.  Left ventricular global longitudinal strain predicts elevated cardiac pressures and poor clinical outcomes in patients with non-ischemic dilated cardiomyopathy.

Authors:  Ieva Kažukauskienė; Giedrė Balčiūnaitė; Vaida Baltrūnienė; Jelena Čelutkienė; Vytė Valerija Maneikienė; Sigitas Čibiras; Kęstutis Ručinskas; Virginija Grabauskienė
Journal:  Cardiovasc Ultrasound       Date:  2021-06-05       Impact factor: 2.062

5.  Effects of human relaxin-2 (serelaxin) on hypoxic pulmonary vasoconstriction during acute hypoxia in a sheep model.

Authors:  René Schiffner; Marius Nistor; Sabine Juliane Bischoff; Georg Matziolis; Martin Schmidt; Thomas Lehmann
Journal:  Hypoxia (Auckl)       Date:  2018-05-22

6.  Cardiovascular magnetic resonance 4D flow analysis has a higher diagnostic yield than Doppler echocardiography for detecting increased pulmonary artery pressure.

Authors:  Joao G Ramos; Alexander Fyrdahl; Björn Wieslander; Gert Reiter; Ursula Reiter; Ning Jin; Eva Maret; Maria Eriksson; Kenneth Caidahl; Peder Sörensson; Andreas Sigfridsson; Martin Ugander
Journal:  BMC Med Imaging       Date:  2020-03-06       Impact factor: 1.930

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.